# Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

> **NCT04540380** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Renal Failure

## Interventions

- **DRUG:** Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab
- **PROCEDURE:** Combined bone marrow and kidney transplant

## Key facts

- **NCT ID:** NCT04540380
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04540380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04540380, "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04540380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*